What is LYEL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.21B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LYEL?

P/E (TTM) is n/a and 52-week range is $8.21 to $45.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LYEL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LYEL?

The company profile lists revenue (TTM) near $28K, net income (TTM) near $-25.76B, EPS (TTM) near $-12.01 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lyell Immunopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 23.3M shares outstanding, ISIN US55083R2031 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 161 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Employees

161

Website

lyell.com/

IPO

2021-06-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)